Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 545Lymphoma 444Precursor Cell Lymphoblastic Leukemia-Lymphoma 409Lymphoma, Large B-Cell, Diffuse 347Leukemia 344Multiple Myeloma 335Lymphoma, Non-Hodgkin 316Leukemia, Myeloid, Acute 288Leukemia, Lymphocytic, Chronic, B-Cell 285Lymphoma, Follicular 241Burkitt Lymphoma 218Myelodysplastic Syndromes 209Lymphoma, Mantle-Cell 201Hodgkin Disease 193Recurrence 153Lymphoma, B-Cell, Marginal Zone 142Melanoma 135Lymphoma, Large-Cell, Immunoblastic 116Neoplasms 109Lymphoma, B-Cell 103Neuroblastoma 101Neoplasms, Plasma Cell 99Ovarian Neoplasms 96Triple Negative Breast Neoplasms 93Leukemia, Myelogenous, Chronic, BCR-ABL Positive 91Myeloproliferative Disorders 87Hematologic Neoplasms 87Leukemia, Myeloid, Chronic-Phase 83Leukemia, Myeloid, Accelerated Phase 80Leukemia, Myelomonocytic, Chronic 78

Interventions

exemestane 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Metastatic Beast Cancer × Cyclophosphamide × Clear all
NCT01963481 2020-03-17

Exemestane and Cyclophosphamide for Metastatic Breast Cancer

NYU Langone Health

Phase 2 Completed
23 enrolled 10 charts

Metastatic Beast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡